PT  - JOURNAL ARTICLE
AU  - Piché-Renaud, Pierre-Philippe
AU  - Panetta, Luc
AU  - Farrar, Daniel S.
AU  - Moore-Hepburn, Charlotte
AU  - Drouin, Olivier
AU  - Papenburg, Jesse
AU  - Salvadori, Marina I.
AU  - Laffin, Melanie
AU  - Kakkar, Fatima
AU  - Morris, Shaun K.
AU  - ,
TI  - Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada
AID  - 10.1101/2022.02.02.22270334
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.02.02.22270334
4099  - http://medrxiv.org/content/early/2022/02/07/2022.02.02.22270334.short
4100  - http://medrxiv.org/content/early/2022/02/07/2022.02.02.22270334.full
AB  - Importance There are limited data on outcomes of SARS-CoV-2 infection among infants (<1 year of age). In the absence of approved vaccines for infants, understanding characteristics associated with hospitalization and severe disease from COVID-19 in this age group will help inform clinical management and public health interventions.Objective The objective of this study was to describe the clinical manifestations, disease severity, and characteristics associated with hospitalization among infants infected with the initial strains of SARS-CoV-2.Design Prospective study of infants with SARS-CoV-2 from April 8th 2020 to May 31st 2021.Setting National study using the infrastructure of the Canadian Paediatric Surveillance Program, reporting inpatients and outpatients seen in clinics and emergency departments.Participants Infants <1 year of age with microbiologically confirmed SARS-CoV-2 infection.Exposure Infant-level characteristics associated with hospitalization for COVID-19.Main outcomes and Measures Cases were classified as either: 1) Non-hospitalized patient with SARS-CoV-2 infection; 2) COVID-19-related hospitalization; or 3) non-COVID-19-related hospitalization (e.g., incidentally detected SARS-CoV-2). Case severity was defined as asymptomatic, outpatient care, mild (inpatient care), moderate or severe disease. Multivariable logistic regression was performed to identify characteristics associated with hospitalization.Results A total of 531 cases were reported, including 332 (62.5%) non-hospitalized and 199 (37.5%) hospitalized infants. Among hospitalized infants, 141 of 199 infants (70.9%) were admitted because of COVID-19-related illness, and 58 (29.1%) were admitted for reasons other than acute COVID-19. Amongst all cases with SARS-CoV-2 infection, the most common presenting symptoms included fever (66.5%), coryza (47.1%), cough (37.3%) and decreased oral intake (25.0%). In our main analysis, infants with a comorbid condition had higher odds of hospitalization compared to infants with no comorbid conditions (aOR=4.53, 2.06-9.97), and infants <1 month had higher odds of hospitalization then infants aged 1-3 months (aOR=3.78, 1.97-7.26). In total, 20 infants (3.8%) met criteria for severe disease.Conclusions and Relevance We describe one of the largest cohorts of infants with SARS-CoV-2 infection. Overall, severe COVID-19 in this age group is uncommon with most infants having mild disease. Comorbid conditions and younger age were associated with COVID-19-related hospitalization amongst infants.Question What are the spectrum of illness, disease severity, and characteristics associated with hospitalization in infants with SARS-CoV-2 infection?Findings A total of 531 cases were reported to the Canadian Paediatric Surveillance Program, including 332 (62.5%) non-hospitalized and 199 (37.5%) hospitalized infants. In total, 20 infants met criteria for severe disease (3.8%). Infants’ characteristics associated with admission included age of less than one month and comorbid conditions.Meaning This study provides data on the spectrum of disease, severity, and characteristics associated with admission due to COVID-19 in infants, which informs clinical management and public health interventions in this specific population.Competing Interest StatementJP reports grants to his institution from MedImmune, Merck, Sanofi Pasteur and AbbVie, and speaker fees from AbbVie and AstraZeneca, all outside of the submitted work. MS is supported via salary awards from the BC Children's Hospital Foundation, the Canadian Child Health Clinician Scientist Program and the Michael Smith Foundation for Health Research. MS has been an investigator on projects funded by GlaxoSmithKline, Merck, Pfizer, Sanofi-Pasteur, Seqirus, Symvivo and VBI Vaccines. All funds have been paid to his institute, and he has not received any personal payments. PPPR has been co-investigator on an investigator-led project funded by Pfizer that is unrelated to this study. RP is a consultant for Verity Pharmaceuticals. SKM is co-principal investigator on an investigator-led grant from Pfizer, has served on an ad-hoc advisory boards for Pfizer and Sanofi Pasteur, and has received speaker fees from GlaxoSmithKline, all unrelated to this study.Funding StatementOD & FK are supported by a Clinical Research Scholars Award, from the Fonds de recherche du Quebec - Sante. We gratefully acknowledge the financial support received from the Public Health Agency of Canada to the Canadian Paediatric Surveillance Program, in support of the COVID-19 study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was obtained from the Public Health Agency of Canada and Health Canada Research Ethics Board (REB 2020-002P), The Hospital for Sick Children (REB 1000070001) and the Institutional Review Board of the Centre Hospitalier Universitaire Sainte-Justine (IRB MP-21-2021-2901) as well as at individual sites, as required by local policies.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript